因研发不及预期、核心资产出售后无接续管线、战略聚焦核心业务等原因,近年来国内外医药行业时不时会传出新药项目终止的消息。如近一个月内,多家国内药企的研发项目就已终止。其中,有的是被药企直接叫停研发项目,还有部分则因为子公司解散对应管线无法再推进。11月14日消息,我武生物公告称,公司管理层决定终止烟曲霉点刺液研发项目,不再开展后续临床试验。该药物用于辅助诊断因烟曲霉致敏引起的I型变态反应性疾病。关于...
Source Link因研发不及预期、核心资产出售后无接续管线、战略聚焦核心业务等原因,近年来国内外医药行业时不时会传出新药项目终止的消息。如近一个月内,多家国内药企的研发项目就已终止。其中,有的是被药企直接叫停研发项目,还有部分则因为子公司解散对应管线无法再推进。11月14日消息,我武生物公告称,公司管理层决定终止烟曲霉点刺液研发项目,不再开展后续临床试验。该药物用于辅助诊断因烟曲霉致敏引起的I型变态反应性疾病。关于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.